Published online 31 March 2009
Haematologica, Vol 94, Issue 5, 738-742 doi:10.3324/haematol.2008.001537
Copyright © 2009 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Troch, M.
Right arrow Articles by Raderer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Troch, M.
Right arrow Articles by Raderer, M.

Multiple Myeloma

A phase II study of bortezomib in patients with MALT lymphoma

Marlene Troch1, Constanze Jonak1, Leonhard Müllauer2, Andreas Püspök3, Michael Formanek4, Wolfgang Hauff5, Christoph C. Zielinski1, Andreas Chott2, Markus Raderer1

1 Medical University of Vienna, Departments of Internal Medicine I, Division of Oncology
2 Internal Medicine III
3 Division of Gastroenterology
4 Pathology
5 Otorhinolaryngology, and Ophthalmology, Vienna, Austria

Correspondence: Markus Raderer, MD, Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. E-mail:markus.raderer{at}meduniwien.ac.at

We have performed a phase II study to evaluate bortezomib in patients with MALT-lymphoma. Sixteen patients entered the trial, 4 had gastric MALT-lymphoma, 7 of the ocular adnexa, one of the colon, and 2 of the parotid, and one patient each the lung and the breast. Bortezomib was given at 1.5 mg/m2 days 1, 4, 8 and 11; repeated every 21 days. The overall response rate was 80% (13/16); 7 patients achieved complete remission (43%), 6 partial response (37%) and 3 stable disease. After a median follow-up of 23 months (range; 8–26), all patients are alive and 4 have relapsed. Fifteen patients required dose reductions due to either neuropathy (7 patients) or diarrhea (8 patients). Bortezomib appears to be active in patients with MALT-lymphoma. However, an unexpectedly high rate of toxicities was seen, warranting assessment of combination schedules with bortezomib at a lower dose than given in our study (ClinicalTrials.govIdentifier: NCT 00373906).

Key words: bortezomib, MALT lymphoma, chemotherapy.